Cat. #156403
USP9x-deficient HCT116 (with or without p53) cell line
Cat. #: 156403
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Tissue: Colon
Disease: Cancer
Model: Knock-Out
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Fred Bunz
Institute: Johns Hopkins University
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: USP9x-deficient HCT116 (with or without p53) cell line
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: HCT 116
- Tissue: Colon
- Disease: Cancer
- Model: Knock-Out
- Description: This cell line presents an opportunity to study the effect of loss of apoptotic control on colorectal cancer cells. Study of deubiquitinase Ups9X could act as a leap towards understanding apoptotic regulation and potentially lead to new drug targets for cancer.In this technology, the gene USP9X is knocked out of two the HCT116 cell line. The gene knockout has been performed by rAAV-mediated homologous recombination. The technology also consists of a double knockout line without USP9X and p53, a tumor suppressor gene.
Target Details
- Target: USP9X and p53
Handling
- Format: Frozen
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Harris et al. 2012. Cancer Biol Ther. 13(13):1319-24. PMID: 22895071.
